These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 8554791)

  • 1. [Huntington disease: clinical and genetic study in a Spanish population].
    Solís Pérez MP; Palau Martínez F; Burguera Hernández JA; Salazar Cifré A
    Neurologia; 1995 Nov; 10(9):362-6. PubMed ID: 8554791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Importance of the number of trinucleotide repeat expansions in the clinical manifestations of Huntington's chorea].
    Vojvodić N; Culjković B; Romac S; Stojković O; Sternić N; Sokić D; Kostić VS
    Srp Arh Celok Lek; 1998; 126(3-4):77-82. PubMed ID: 9863360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychiatric and cognitive difficulties as indicators of juvenile huntington disease onset in 29 patients.
    Ribaï P; Nguyen K; Hahn-Barma V; Gourfinkel-An I; Vidailhet M; Legout A; Dodé C; Brice A; Dürr A
    Arch Neurol; 2007 Jun; 64(6):813-9. PubMed ID: 17562929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Psychometric study in Huntington disease].
    Pasquier F; Cabaret M; Petit H
    Encephale; 1993; 19(4):303-11. PubMed ID: 8275917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unified Huntington's disease rating scale: clinical practice and a critical approach.
    Klempír J; Klempírova O; Spacková N; Zidovská J; Roth J
    Funct Neurol; 2006; 21(4):217-21. PubMed ID: 17367582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Huntington chorea. Clinical correlations and preliminary neuropsychological data].
    Fragassi NA; Stanzione M; Angelini R; Di Maio L
    Acta Neurol (Napoli); 1992; 14(4-6):530-6. PubMed ID: 1293994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The gene responsible for Huntington's disease in Spanish families: its diagnostic value and the relation between trinucleotide expansion and the clinical characteristics].
    Benítez J; Fernández E; García Ruiz P; Robledo M; Ayuso C; García Yébenes J
    Rev Clin Esp; 1994 Aug; 194(8):591-3. PubMed ID: 7938836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What is the impact of education on Huntington's disease?
    López-Sendón JL; Royuela A; Trigo P; Orth M; Lange H; Reilmann R; Keylock J; Rickards H; Piacentini S; Squitieri F; Landwehrmeyer B; Witjes-Ane MN; Jurgens CK; Roos RA; Abraira V; de Yébenes JG;
    Mov Disord; 2011 Jul; 26(8):1489-95. PubMed ID: 21432905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of neuropathological severity in 100 patients with Huntington's disease.
    Rosenblatt A; Abbott MH; Gourley LM; Troncoso JC; Margolis RL; Brandt J; Ross CA
    Ann Neurol; 2003 Oct; 54(4):488-93. PubMed ID: 14520661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parameter-based assessment of spatial and non-spatial attentional deficits in Huntington's disease.
    Finke K; Bublak P; Dose M; Müller HJ; Schneider WX
    Brain; 2006 May; 129(Pt 5):1137-51. PubMed ID: 16504973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of simple movements reflects impairment in Huntington's disease.
    Saft C; Andrich J; Meisel NM; Przuntek H; Müller T
    Mov Disord; 2006 Aug; 21(8):1208-12. PubMed ID: 16700032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Analysis of trinucleotide repeat expansion as a new mechanism of mutation in Huntington's chorea: theoretical and applied aspects].
    Illarioshkin SN; Ivanova-Smolenskaia IA; Markova ED; Nikol'skaia NN; Chabrashvili TZ; Insarova NG
    Genetika; 1996 Jan; 32(1):103-9. PubMed ID: 8647411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cognitive assessment of asymptomatic Huntington's disease carriers].
    Gómez-Tortosa E; del Barrio Alba A; Sánchez Pernaute R; Benítez J; Barroso A; García Yébenes J
    Neurologia; 1997; 12(6):226-31. PubMed ID: 9303588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of CAG repeat length on psychiatric disorders in Huntington's disease.
    Vassos E; Panas M; Kladi A; Vassilopoulos D
    J Psychiatr Res; 2008 Jun; 42(7):544-9. PubMed ID: 17610899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early cognitive deficits in Swedish gene carriers of Huntington's disease.
    Robins Wahlin TB; Lundin A; Dear K
    Neuropsychology; 2007 Jan; 21(1):31-44. PubMed ID: 17201528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Juvenile-onset huntington disease: a matter of perspective.
    Biglan K; Shoulson I
    Arch Neurol; 2007 Jun; 64(6):783-4. PubMed ID: 17562925
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of rivastigmine on motor and cognitive impairment in Huntington's disease.
    de Tommaso M; Specchio N; Sciruicchio V; Difruscolo O; Specchio LM
    Mov Disord; 2004 Dec; 19(12):1516-8. PubMed ID: 15390067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors contributing to institutionalization in patients with Huntington's disease.
    Rosenblatt A; Kumar BV; Margolis RL; Welsh CS; Ross CA
    Mov Disord; 2011 Aug; 26(9):1711-6. PubMed ID: 21538527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in Huntington's disease diagnostics: development of a standard reference material.
    Levin BC; Richie KL; Jakupciak JP
    Expert Rev Mol Diagn; 2006 Jul; 6(4):587-96. PubMed ID: 16824032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prefrontal cortex volume reduction on MRI in preclinical Huntington's disease relates to visuomotor performance and CAG number.
    Gómez-Ansón B; Alegret M; Muñoz E; Monté GC; Alayrach E; Sánchez A; Boada M; Tolosa E
    Parkinsonism Relat Disord; 2009 Mar; 15(3):213-9. PubMed ID: 18632301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.